Beth Toste Harrison, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Lobular | 4 | 2022 | 480 | 0.980 |
Why?
|
Breast Neoplasms | 14 | 2022 | 21187 | 0.930 |
Why?
|
Inflammatory Breast Neoplasms | 4 | 2023 | 154 | 0.690 |
Why?
|
Receptor, erbB-3 | 1 | 2020 | 143 | 0.630 |
Why?
|
Receptors, Nerve Growth Factor | 1 | 2019 | 200 | 0.620 |
Why?
|
Breast Neoplasms, Male | 1 | 2019 | 212 | 0.590 |
Why?
|
Gene Fusion | 1 | 2019 | 357 | 0.550 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2022 | 933 | 0.500 |
Why?
|
Receptor, erbB-2 | 3 | 2022 | 2606 | 0.500 |
Why?
|
Pathology, Surgical | 1 | 2016 | 150 | 0.500 |
Why?
|
Pathology, Clinical | 1 | 2019 | 377 | 0.490 |
Why?
|
Broad Ligament | 1 | 2014 | 5 | 0.480 |
Why?
|
Fibroma | 1 | 2016 | 200 | 0.470 |
Why?
|
Peritoneum | 1 | 2015 | 231 | 0.460 |
Why?
|
Immunohistochemistry | 6 | 2020 | 11119 | 0.460 |
Why?
|
Carcinoma | 4 | 2020 | 2340 | 0.460 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2018 | 1093 | 0.440 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2018 | 737 | 0.440 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2017 | 526 | 0.440 |
Why?
|
Adnexal Diseases | 1 | 2014 | 105 | 0.430 |
Why?
|
Ovarian Diseases | 1 | 2014 | 137 | 0.420 |
Why?
|
Pleural Effusion | 1 | 2016 | 345 | 0.420 |
Why?
|
Breast | 3 | 2023 | 1976 | 0.410 |
Why?
|
Edema | 1 | 2014 | 766 | 0.340 |
Why?
|
Endometrial Neoplasms | 4 | 2020 | 1386 | 0.330 |
Why?
|
Leiomyoma | 1 | 2014 | 644 | 0.330 |
Why?
|
Medical Errors | 1 | 2016 | 1262 | 0.300 |
Why?
|
Patient Selection | 2 | 2020 | 4265 | 0.290 |
Why?
|
Axilla | 2 | 2022 | 625 | 0.290 |
Why?
|
Endometriosis | 1 | 2015 | 874 | 0.280 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2181 | 0.260 |
Why?
|
Carcinoma, Endometrioid | 2 | 2020 | 277 | 0.260 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1166 | 0.250 |
Why?
|
Lymphatic Metastasis | 3 | 2022 | 2916 | 0.230 |
Why?
|
Paget Disease, Extramammary | 1 | 2023 | 51 | 0.210 |
Why?
|
Carcinoma, Transitional Cell | 2 | 2023 | 798 | 0.190 |
Why?
|
Keratins | 1 | 2022 | 502 | 0.180 |
Why?
|
Paris | 1 | 2019 | 41 | 0.170 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2022 | 356 | 0.170 |
Why?
|
Ovarian Neoplasms | 1 | 2016 | 4919 | 0.160 |
Why?
|
DNA Copy Number Variations | 3 | 2023 | 2055 | 0.160 |
Why?
|
Mucins | 1 | 2022 | 571 | 0.160 |
Why?
|
Proto-Oncogene Proteins c-ets | 1 | 2019 | 314 | 0.160 |
Why?
|
Female | 26 | 2023 | 397464 | 0.160 |
Why?
|
Body Surface Area | 1 | 2009 | 206 | 0.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 196 | 0.150 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2022 | 906 | 0.150 |
Why?
|
DNA Polymerase II | 1 | 2018 | 104 | 0.140 |
Why?
|
Sarcoma, Endometrial Stromal | 1 | 2018 | 93 | 0.140 |
Why?
|
14-3-3 Proteins | 1 | 2018 | 222 | 0.140 |
Why?
|
Cadherins | 1 | 2022 | 906 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2525 | 0.140 |
Why?
|
Carcinoma in Situ | 1 | 2022 | 788 | 0.130 |
Why?
|
DNA Repair Enzymes | 1 | 2018 | 346 | 0.130 |
Why?
|
Nipples | 1 | 2018 | 229 | 0.130 |
Why?
|
Gene Amplification | 1 | 2020 | 1099 | 0.130 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2023 | 2250 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2019 | 498 | 0.120 |
Why?
|
Uterine Hemorrhage | 1 | 2016 | 237 | 0.120 |
Why?
|
Necrosis | 1 | 2019 | 1621 | 0.120 |
Why?
|
Diagnosis, Differential | 4 | 2018 | 13020 | 0.120 |
Why?
|
Cytodiagnosis | 1 | 2017 | 453 | 0.110 |
Why?
|
Genital Neoplasms, Female | 1 | 2009 | 538 | 0.110 |
Why?
|
Humans | 28 | 2023 | 768887 | 0.110 |
Why?
|
Mucin-1 | 1 | 2017 | 539 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2023 | 2986 | 0.100 |
Why?
|
Biopsy, Needle | 1 | 2017 | 1627 | 0.100 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1273 | 0.100 |
Why?
|
Pelvis | 1 | 2016 | 738 | 0.100 |
Why?
|
Lymph Nodes | 1 | 2022 | 3473 | 0.090 |
Why?
|
Genetic Association Studies | 1 | 2020 | 2747 | 0.090 |
Why?
|
Middle Aged | 12 | 2022 | 223740 | 0.090 |
Why?
|
Syndrome | 1 | 2016 | 3274 | 0.080 |
Why?
|
Hysterectomy | 1 | 2014 | 866 | 0.080 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15471 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2021 | 9442 | 0.080 |
Why?
|
DNA | 1 | 2022 | 7214 | 0.080 |
Why?
|
Biopsy | 2 | 2021 | 6805 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3671 | 0.070 |
Why?
|
Adult | 9 | 2022 | 223818 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2018 | 2960 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2020 | 20244 | 0.070 |
Why?
|
Antineoplastic Agents | 3 | 2020 | 13699 | 0.070 |
Why?
|
Retrospective Studies | 7 | 2021 | 81892 | 0.060 |
Why?
|
Polyglutamic Acid | 1 | 2005 | 47 | 0.060 |
Why?
|
Aged, 80 and over | 6 | 2020 | 59738 | 0.060 |
Why?
|
Guided Tissue Regeneration | 1 | 2005 | 88 | 0.060 |
Why?
|
Genetic Variation | 1 | 2020 | 6610 | 0.060 |
Why?
|
Melanoma | 1 | 2023 | 5709 | 0.060 |
Why?
|
Aged | 7 | 2022 | 171790 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9549 | 0.060 |
Why?
|
Neurites | 1 | 2005 | 390 | 0.050 |
Why?
|
Ultrasonography | 1 | 2016 | 6001 | 0.050 |
Why?
|
Clinical Trials as Topic | 1 | 2018 | 8055 | 0.050 |
Why?
|
Pyrroles | 1 | 2005 | 1126 | 0.040 |
Why?
|
Mammography | 2 | 2021 | 2434 | 0.040 |
Why?
|
Hormones | 1 | 2022 | 871 | 0.040 |
Why?
|
Polymers | 1 | 2005 | 1632 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1154 | 0.040 |
Why?
|
Neoplasm Metastasis | 2 | 2018 | 4926 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2021 | 36861 | 0.030 |
Why?
|
Gene Dosage | 1 | 2020 | 1222 | 0.030 |
Why?
|
Nausea | 1 | 2009 | 682 | 0.030 |
Why?
|
Carboplatin | 1 | 2009 | 799 | 0.030 |
Why?
|
Prognosis | 3 | 2022 | 30044 | 0.030 |
Why?
|
DNA Mismatch Repair | 1 | 2018 | 432 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2022 | 976 | 0.030 |
Why?
|
North America | 1 | 2018 | 1290 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2252 | 0.030 |
Why?
|
Kinetics | 1 | 2021 | 6334 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2018 | 1836 | 0.030 |
Why?
|
Gene Rearrangement | 1 | 2018 | 1148 | 0.030 |
Why?
|
RNA | 1 | 2023 | 2727 | 0.030 |
Why?
|
Mastectomy | 1 | 2021 | 1850 | 0.030 |
Why?
|
Young Adult | 1 | 2019 | 60110 | 0.030 |
Why?
|
Paclitaxel | 1 | 2009 | 1735 | 0.020 |
Why?
|
Treatment Outcome | 2 | 2018 | 65485 | 0.020 |
Why?
|
United States | 1 | 2019 | 73180 | 0.020 |
Why?
|
Fever | 1 | 2009 | 1620 | 0.020 |
Why?
|
Adolescent | 1 | 2019 | 89247 | 0.020 |
Why?
|
Europe | 1 | 2018 | 3441 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1339 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2009 | 1181 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2018 | 3629 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2018 | 4123 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8559 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10115 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2018 | 2848 | 0.020 |
Why?
|
Body Weight | 1 | 2009 | 4628 | 0.020 |
Why?
|
Administration, Oral | 1 | 2016 | 4042 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12093 | 0.020 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2016 | 3621 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12563 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2016 | 6546 | 0.020 |
Why?
|
Cell Enlargement | 1 | 2005 | 59 | 0.020 |
Why?
|
Spectrophotometry, Infrared | 1 | 2005 | 117 | 0.020 |
Why?
|
Electrochemistry | 1 | 2005 | 146 | 0.020 |
Why?
|
Male | 2 | 2023 | 365249 | 0.020 |
Why?
|
Polylysine | 1 | 2005 | 131 | 0.020 |
Why?
|
Mutation | 2 | 2020 | 30266 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2009 | 11262 | 0.010 |
Why?
|
Laminin | 1 | 2005 | 406 | 0.010 |
Why?
|
Neurofilament Proteins | 1 | 2005 | 337 | 0.010 |
Why?
|
Ganglia, Spinal | 1 | 2005 | 530 | 0.010 |
Why?
|
Cell Count | 1 | 2005 | 1833 | 0.010 |
Why?
|
Body Mass Index | 1 | 2009 | 13054 | 0.010 |
Why?
|
Nerve Regeneration | 1 | 2005 | 799 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2016 | 17174 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11886 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39394 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2016 | 18366 | 0.010 |
Why?
|
Time Factors | 1 | 2018 | 40266 | 0.010 |
Why?
|
Cohort Studies | 1 | 2018 | 41800 | 0.010 |
Why?
|
Prospective Studies | 1 | 2020 | 54950 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2016 | 13593 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 74971 | 0.010 |
Why?
|
Animals | 2 | 2016 | 169408 | 0.010 |
Why?
|
Mice | 1 | 2016 | 82074 | 0.010 |
Why?
|
Rats | 1 | 2005 | 23847 | 0.000 |
Why?
|
Neurons | 1 | 2005 | 9524 | 0.000 |
Why?
|